Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study

[1] Benson AB(2009)Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 15 370-398

[2] Venook AP(2012)Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial J Clin Oncol 30 3353-3360

[3] Cederquist L(2005)Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2696-2704

[4] Chan E(2017)Colorectal cancer statistics, 2017 CA Cancer J Clin 67 177-193

[5] Chen YJ(1999)Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 2061-2067

[6] Cooper HS(2004)American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 3408-3419

[7] Tournigand C(2012)ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 23 2479-2516

[8] Andre T(2018)Adequate lymph node evaluation in the elderly is associated with improved survival in patients with stage I-III colon cancer: a validation study using the National Cancer Data Base Eur J Surg Oncol 44 148-156

[9] Bonnetain F(2010)Perineural invasion: correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer J Clin Oncol 28 e358-e360

[10] Chibaudel B(2017)Perineural invasion is a major prognostic and predictive factor of response to adjuvant chemotherapy in stage I-II colon cancer Ann Surg Oncol 24 1077-1084

[1] Benson AB(2009)Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 15 370-398

[2] Venook AP(2012)Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial J Clin Oncol 30 3353-3360

[3] Cederquist L(2005)Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2696-2704

[4] Chan E(2017)Colorectal cancer statistics, 2017 CA Cancer J Clin 67 177-193

[5] Chen YJ(1999)Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 2061-2067

[6] Cooper HS(2004)American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 3408-3419

[7] Tournigand C(2012)ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 23 2479-2516

[8] Andre T(2018)Adequate lymph node evaluation in the elderly is associated with improved survival in patients with stage I-III colon cancer: a validation study using the National Cancer Data Base Eur J Surg Oncol 44 148-156

[9] Bonnetain F(2010)Perineural invasion: correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer J Clin Oncol 28 e358-e360

[10] Chibaudel B(2017)Perineural invasion is a major prognostic and predictive factor of response to adjuvant chemotherapy in stage I-II colon cancer Ann Surg Oncol 24 1077-1084